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1. Introduction 
Neovasculogenesis is a multi-stage process of blood vessel formation which plays a vital 
role in neoplasia. The formation of blood vessels in tumours is closely related to invasive 
cancerous growth.  
The process of angiogenesis is closely regulated by the system of cooperating stimulants and 
inhibitors. Factors stimulating neovasculogenesis are characterised by a fairly broad 
spectrum of activity. Three key attributes of proangiogenic factors have been identified  
as:  
1. The specific effect on endothelial cells, i.e. the given factor’s presence induces 
angiogenesis.  
2. The presence of specific receptors in endothelial cells.  
3. Neutralisation of the factor inhibits angiogenesis (Grunstein et al., 1999; McMahon, 
2000; Szala & Radzikowski, 1997). 
There are a number of proteins that have been referred to as pro-angiogenic factors that 
actively participate in the formation of capillaries. VEGF meets all key requirements of being 
classified as a pro-angiogenic factor: it specifically affects vascular epithelial cells, it is 
present only during angiogenesis, it does not occur in adults unless new vessels are being 
formed. Its overexpression is connected to the formation of capillaries and its neutralisation 
inhibits the process (Grunstein et al., 1999; McMahon, 2000). 
2. VEGF - Vascular Endothelial Growth Factor 
The two main biological activities of VEGF - mitogenic activity and vascular permeability 
inducing activity - were described, purified and designated independently as VPF (vascular 
permeability factor) and VEGF (vascular endothelial growth factor). 
The release of a vascular permeability-increasing agent by guinea pig hepatocarcinoma cells 
was reported in 1979 (Dvorak et al., 1979). Vascular leakage was subsequently used to 
monitor purification of VEGF from the supernatant of this (Senger et al., 1983; Senger et al., 
1986) and of the human histiocytic lymphoma cell line U-937 (Connolly et al., 1989b). 
Therefore, the factor was later designated as vascular permeability factor –VPF ( Senger et 
al., 1983) or vasculotropin (Plouët et al., 1989).  
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The mitogenic activity of this agent towards vascular endothelial cells was used to monitor 
its purification, and on the basis of its target cell selectivity the purified agent was 
designated VEGF (Ferrara & Henzel, 1989; Gospodarowicz et al., 1989). 
VEGF is a strong and specific mitogen for endothelial vascular cells of the circulatory and 
lymphatic systems (Baillie et al., 2001; Barańska et al., 2005; Chhieng et al., 2003). It is 
secreted by a number of cell types: T lymphocytes, monocytes, macrophages, activated 
platelets, fibroblasts, smooth muscle cells, and most importantly neoplastic cells 
(Namiecińska et al., 2005; Restucci et al., 2002; Rosen, 2002; Szala & Radzikowski, 1997). The 
factor is characterised by mitogenic activity towards endothelial cells, which causes their 
increased proliferation, migration and formation of new vessels from endothelial cells 
(Baillie et al., 2001; Bałan, 2000; Breier & Risau, 1996; Conti, 2002; Dvorak, 2002; Epstein et 
al., 2001; Gawrychowski et al., 1997; Nicosia, 1998; Restucci et al., 2002; Rofstad & Halsor, 
2000; Terman & Stoletov, 2001). The newly formed blood vessels serve not only to provide 
neoplastic cells with nutrients and oxygen, but are also responsible for the neoplastic cells 
permeating to the circulatory system, thus facilitating tumour dissemination and metastasis 
(Litwiniuk et al., 2007).  
VEGF is also a 50 times stronger inductor of blood vessel permeability than histamine, it 
allows the permeation of plasma proteins as well as neoplastic cells into the extravascular 
space, allowing for their hyperplasia into the new location (Epstein et al, 2001; Kondo et al., 
2000; Łojko & Komarnicki, 2004; Szala & Radzikowski, 1997).  
VEGF is the main proangiogenic factor responsible for the formation of blood vessels in 
neoplastic tumours (Fang et al., 2001; Papetti & Herman, 2002). 
It was demonstrated that the increase of VEGF-A expression is one of the mechanisms 
greatly enhances a tumour’s resistance to chemotherapy (Volk et al., 2008). VEGF-A protects 
tumor cells from apoptosis through autocrine activation of VEGF-A receptors expressed on 
tumour cells ( Volk et al., 2011). 
2.1 VEGF–A isoforms 
VEGF is a glycosilated homodimer whose molecular mass is 46-48 kDa (Barańska et al., 
2005, Chhieng et al., 2003; Clifford et al., 2001; Kondo et al., 2000; Nicosia, 1998; Papetti & 
Herman, 2002; Ranieri et al., 2004). The gene for VEGF-A is located on chromosone 6 at band 
21.3, and comprises 8 exons separated by 7 introns (Ferrara, 1999; Gruchlik et al., 2007). 
Through alternative mRNA maturation, isoforms of VEGF are formed comprising 
respectively 121, 145, 148, 162, 165, 183, 189, or 206 amino acids ( VEGF121, VEGF145, VEGF148, 
VEGF183, VEGF165, VEGF189, VEGF206). The shortest isoform, VEGF121, is encoded by exons 1-5 
and 8, VEGF165 includes additionally exon 7. VEGF189 and VEGF206 mRNAs contain all 8 
exons, and the usage of a variable 5'-splice donor site within exon 6 creates the difference 
between the VEGF189 and VEGF206 mRNA .The particular isoforms vary in terms of 
biochemical and biological qualities (Bałan, 2000; Barańska et al., 2005; Ferrara, 1999; Ferrara 
& Davis-Smyth 1997; Łojko & Komarnicki, 2004; Łukasik et al., 2003; Namiecińska et al., 
2005; Nicosia, 1998; Oshika et al., 1998; Papetti & Herman, 2002; Webb et al., 1998; Yu et al., 
2002). Additionally, a form of VEGF110 also exists as a product of VEGF165 and VEGF 189 
proteolysis.  
The most common form, synthesised by a wide range of both healthy and altered cells, 
which is at the same time the most active biologically, is VEGF165 and VEGF121 ( Gruchlik et 
al., 2007). Other commonly observed isoforms are VEGF121, VEGF165, VEGF189, while 
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VEGF145, VEGF183 and VEGF206 are rarely observed in vivo, e.g. the longest of the forms is 
found exclusively in embryonic tissues (Barańska et al., 2005). VEGF121 and VEGF165 are 
soluble proteins observed extracellularly. VEGF121 is a weak acidic polypeptide that does not 
bind to heparin due to the lack of the heparin-binding domain encoded by exons 6 and 7. In 
contrast, VEGF165 is basic and binds to heparin. VEGF189 and VEGF206 are even more basic 
and bind to heparin with greater affinity. The differences in affinity for heparin affect the 
fate of the VEGF isoforms (Houck et al., 1992). VEGF121 is secreted and is freely diffusible in 
the medium of transfected cells. VEGF165 is also secreted but a significant fraction remains 
bound to heparin-containing proteoglycans. A part of VEGF165 remains anchored to the cell 
membrane and the extracellular matrix. VEGF189 and VEGF206 are alkaline and are found 
almost exclusively as proteins anchored to the extracellular matrix. They display stronger 
mitogenic activity than the shorter isoforms (Barańska et al., 2005; Gruchlik et al., 2007; 
Łojko & Komarnicki, 2004; Łukasik et al., 2003). They may take the soluble form after 
binding with heparin as well as under the effect of heparinase, metaloproteases or other 
extracellular proteases. The mRNA molecule for all the isoforms comprises exons 1-5 
carrying information necessary to recognise the specific receptors – VEGFR-1 or VEGFR-2. 
Discrepancies in this respect are observed only in terms of presence or absence of exons 6, 6’, 
7 or 8. ( Michalski et al., 2003) 
2.2 The VEGF protein family 
Purified VEGF (VEGF-A) was first obtained by Gospodarowicz et al. and Ferrara and 
Hanzel in 1989 (Ferrara & Henzel, 1989; Gospodarowicz et al., 1989). It is one of the most 
thoroughly studied factors partaking in all stages of angiogenesis.  
In normal tissues, the highest levels of VEGF-A mRNA are found in adult lung, kidney, 
heart, and adrenal gland. Lower, but still readily detectable, quantities of VEGF-A transcript 
levels occur in liver, spleen, and gastric mucosa (Hoeban et al., 2004) 
VEGF-A displays a variety of qualities, one of the most important of which is the increase of 
vascular permeability. The same allows blood proteins, e.g. plasminogen, fibrinogen, 
macrophages and platelets to permeate into the extravascular space.  
Plasmitogen is transformed into plasmin which, through proteolytic action, activates 
metalloproteases destroying the basement membranes of the existing vessels. Fibrinogen is 
transformed into fibrin which provides a form of scaffold for the precipitating endothelial 
cells. Macrophages and platelets in turn stimulate angiogenesis by secreting cytokines and 
VEGF.  
VEGF-A is the key mitogenic factor but it also displays strong protective action. It was 
observed that it can induce the expression of proteins which prevent apoptosis in blood 
vascular endothelial cells and increase the probability of the cells’ survival ( Hoeban et al., 
2004; Bałan & Słowiński, 2008) 
It was demonstrated that overexpression VEGF may inhibit differentiation and maturation 
of dendritic cells and thus weaken the host immunological response against a tumour 
(Swidzińska et al., 2006). 
Furthermore, VEGF stimulates the expression of the tissue factor (TF) in ECs and 
monocytes, which facilitates the activation of blood coagulation (Wojtkiewicz & Sierko, 
2009). 
At a molecular level, VEGF-A reprograms endothelial cell gene expression, leading to 
increased expression of a number of different proteins, including the procoagulant tissue 
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factor, proteins associated with the fibrinolytic pathway, matrix metalloproteases, the 
GLUT-1 glucose transporter, nitric oxide synthase, numerous mitogens, and a number of 
antiapoptotic factors (e.g. bcl-2, A1, survivin, XIAP)( Bałan & Słotwiński 2008). 
VEGF-A is a cytokine which plays a key role in postnatal angiogenesis, both pathological, 
i.e. the formation of undesirable vessels (in tumours, retinopathy), and physiological 
(healing).  
VEGF-A is over expressed not only by invasive cancer cells, but also by at least some 
premalignant lesions (eg, precursor lesions of breast, cervix, and colon cancers);furthermore, 
expression levels increased in parallel with malignant progression (Bałan & Słotwiński 2008). 
The VEGF group also includes other structurally related, yet varying in terms of biological 
activity, proteins VEGF-B, VEGF-C, VEGF-D and VEGF-E as well as the placental growth 
factor (PIGF) (Barańska et al., 2005; Łojko & Komarnicki, 2004; Namiecińska et al., 2005; 
Papetti & Herman, 2002; Ranieri et al., 2004; Terman & Stoletov, 2001).  
Cytokine VEGF-B was discovered in 1996 ( Grimmond et al., 1996; Olofsson et al., 1996). Its 
gene is located in the region of the 11q13 chromosome and contains 7 exons. 
It is observed in two forms formed through alternative splicing of mRNA contained in 
molecule 167 or 186 of amino acids. VEGF-B is a VEGFR-1 ligand, and after the formation of 
the heterodimer from VEGF-A it can also react with the VEGF-2 receptor (Olofsson et al., 
1998) The two splice isoforms, VEGF-B167 and VEGF-B186, differ in their C-terminal amino 
acid sequences and show different diffusion properties and receptor-binding affinities. Both 
isoforms are expressed in adult tissues, with the highest expression in the myocardium, 
brown adipose tissue (BAT), skeletal muscle and pancreas. The expression of VEGF-B is not 
induced by hypoxia, in contrast to all the other VEGF-ligands (Li et al., 2001) 
VEGF –B167 has a heparyn-binding domain so that upon secretion, VEGF –B167 binds to cell- 
surface heparyn sulphate proteoglycans. VRGF-B186 does not contain the heparin-binding 
domain and there-fore is more soluble ( Li, 2010) 
Several studies have shown that VEGF-B gene or protein transfer into different types of 
organs did not induce angiogenesis under most conditions (Li et al., 2009) 
VEGF-B is not necessary in the process of angiogenesis, however, recent studies have shown 
that the factor is needed for vessel survival. In fact many researchers have suggested 
changing the VEGF-B functional denotation to “survival” rather than an “angiogenic” 
factor.  
We recently found that VEGF-B is a survival factor for multiple types of vascular cells, 
including vascular endothelial cells (EC), pericytes (PC) and smooth muscle cells (SMC) 
(Zhang et al., 2009). 
VGF-B186 delivery to the heart upregulated the expression of many antiapoptotic genes in 
cardiomyocytes, and inhibited cardiac myocyte apoptosis, demonstrating a survival effect of 
VEGF-B186 on them (Lahteenvuo et al., 2009). 
Certain researchers claim VEGF-B to be necessary in adults to ensure proper functioning, 
however, it is not required in the development of the cardiovascular system and 
angiogenesis (Roskoski, 2007) 
Moreover, Dr Eriksson’s group showed that VEGF-B is a critical regulator of energy 
metabolism by regulating fatty acid uptake ( Hagberg et al., 2010) 
It has also been observed that the protein can regulate the FATP (Fatty Acid Transport 
Proteins) level in vascular walls. 
The human VEGF-C gene was first cloned in 1996, while VEGF-D in 1997 (Joukov V et al. 
1996; Yamada Y 1997). 
www.intechopen.com
 
The Role of VEGF in the Process of Neovasculogenesis 
 
185 
Both factors are synthesised as inactive, multi-molecular pre-pro-proteins comprising end 
pro-peptides NH2- and COOH – and the central homological VEGF domain. The domain 
contains receptor binding sites (Achen et al., 1998; Joukov et al., 1996; Stacker et al.,1999; 
Yamada 1997; Kuuk et al., 1996). 
The active VEGF-C and VEGF-D forms are formed through inter- and extra-cellular 
proteolysis of –C and –N ends (Achen et al., 1998; Joukov et al., 1996). 
The precursor forms of the growth factor interact mainly with the VEGFR-3 receptor while 
active forms display strong affinity for VEGFR-2 ( Joukov et al., 1997; Stacker et al., 1999). 
The functions of VEGF-C and VEGF-D are mainly determined by the receptor they bind 
with and its location. When either of the factors interacts with the VEGFR-3 receptor located 
in the lymphatic epithelium, they induce the development and restructuring of lymphatic 
vessels. In turn, when the active forms of the growth factor bind with the VEGFR-2 receptor 
in blood vessel epithelium, they influence angiogenesis.  
In the course of research conducted on embryos and transgenic animals, it was observed 
that VEGF-C and the VEGFR-3 receptor play a vital role in the embryonic development of 
the lymphoid system. Homozygous mice VEGF-C-/- with inactive VEGF-C gene died due to 
undeveloped lymphoid system. Heterozygous mice VEGF-C -/+ displayed significant 
malformation in terms of this system.  
In adult humans, high levels of VEGF-C mRNA have been observed in a number of organs, 
i.e.: the heart, lungs, skeletal muscles, large intestine, small intestine, and thyroid. Relatively 
small amounts of VEGF-C are known to be produced in the kidneys, pancreas, prostate, and 
spleen (Roskoski 2007). 
VEGF-C overexpression has been observed in a number of tumours in humans, including: 
breast cancer, colorectal cancer, stomach cancer, thyroid neoplasm, and prostate cancer. 
High levels of the factor indicate a negative prognosis (Sucha & Ganesan 2008) 
Structural similarities between VEGF-C and VEGF-D as well as their affinity for the VEGFR-
2 and VEGFR-3 receptors would suggest similar biological qualities of the two. However, 
VEGF-D does not play as significant a role in the embryonic development of the lymphoid 
system (Karkkainen et al., 2004). It has been observed that apart from mitogenic activity on 
endothelial cells, it also stimulates fibroblast division.  
High VEGF-D levels are observed in humans mainly in the heart, lungs, skeletal muscles, 
and small intestine. VEGF-D overexpression is observed in a number of tumours as well, 
i.e.: breast cancer, colorectal cancer, stomach cancer, thyroid neoplasm, and cervical cancer. 
Furthermore, the VEGF-D expression level has proved to be an independent prognostic 
factor in respect to ovarian cancer (Yokoyama et al 2003). 
To sum up, VEGF-C and VEGF-D play important roles in lymphangiogenesis and 
angiogenesis, they also facilitate lymphatic metastasis in lymph nodes.  
VEGF-E was identified in the genome of the orf virus (parapoxvirus) which is pathogenic in 
goats, sheep and sporadically in humans. It is in homological sequence with other proteins 
of the VEGF family, which may suggest that the gene of the virus VEGF originated from 
mammal hosts and underwent a genetic drift. It displays proangiogenic activity (Barańska et 
al., 2005).  
PIGF – occurs in homodimer form. Increased concentrations of this factor have been 
observed in cases of myocardial infarction, retinopathy and neoplastic disease. It is 
responsible for stimulating the growth of endothelial cells and smooth muscles. Through 
action synergistic with VEGF-B, it influences the diversification and activation of monocytes 
(Clauss, 2000; Namiecińska et al., 2005).  
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The VEGF family also includes sv-VEGF proteins isolated from snake venom. Due to their 
homology similar to the VEGF found in mammals, they are often referred to as “VEGF-like” 
proteins. One such protein has been isolated from the venom of a Bothrops insularis snake 
(Barańska et al., 2005).  
2.3 VEGF receptors 
VEGF binds to at least three different types of receptors: VEGFR-1 (Flt-1- fms-like tyrosine 
kinase-1), VEGFR-2 (KDR- kinase domain region in humans and Flk-1- fetal liver kinase-1 in 
mice), and VEGFR-3 (Flt-4 – fetal liver kinase 4) which belong to a family of receptors 
containing a tyrosine-kinase domain (Bałan, 2000; Barańska et al, 2005; Breier & Risau, 1996; 
Ferrara & Davis-Smyth, 1997; Namiecińska et al., 2005; Papetti, 2002; Ranieri et al., 2004; 
Szala & Radzikowski, 1997; Webb et al., 1998).  
VEGFR-1 is found in the epithelium, as well as on the surface of macrophages and monocytes. 
The receptor is characterised by the highest affinity for the ligand (Kd-10-20 pM). Its 
expression remains constant in dividing as well as latent cells. It has been observed that the 
absence of said receptor results in disorders in terms of the structure and morphology of the 
formed vessels. The same is due to the increase in the number of hemangioblasts accumulating 
inside the forming vessels and closing them off (Barańska et al., 2005).  
In homozygous mice, the receptor’s insufficiency leads to vessel hypertrophy and 
premature death of foetuses in mid pregnancy (Hucz & Szala, 2006).  
VEGFR-1 displays significant affinity for bonding VEGF-A as well as PIGF and VEGF-B 
(Barańska et al., 2005).  
VEGFR-2 is expressed in epithelium cells, retinal stem cells, as well as platelets and 
hematopoietic cells, mainly during foetal life when the processes of angiogenesis and 
vasculogenesis are particularly intensive (Bałan, 2000). The amount of mRNA for VEFGR-2 is 
reduced in the cells of an adult organism. Embryos deprived of the VEGFR-2 receptor do not 
develop vascularisation and die in early embryogenesis (Shibuya & Claesson-Welsh 2006) The 
receptor’s affinity for the ligand is lower than in the case of VEGFR-1 (Barańska et al., 2005).  
The Flt-1 and KDR/Flk-1 receptors vary in terms of signal transduction mechanisms. 
Stimulation of the KDR/Flk-1 receptor results in a violent reaction while stimulation of the 
Flt-1 receptor induces a significantly weaker response. The above suggests that Flt-1 may 
negatively regulate the process of angiogenesis (Ferrara, 1999), whereas activation of the 
KDR/Flk-1 receptor increases the proliferational activity of endothelium cells while at the 
same time inhibiting the process of apoptosis and increasing blood vessel permeability. It 
has been observed that mouse embryos deprived of the VEGFR-2 receptor will be non-
vascularised and will die in the early stage of embryogenesis (Thielemann et al., 2010). The 
receptor reacts to VEGF-C and VEGF D.  
Two distinct receptor tyrosine kinases have been identified for VEGF-A on endothelial cells: 
VEGFR-1 and VEGFR-2 (Olsson et al., 2006; Shibuya & Claesson-Welsh, 2006). The affinity 
of VEGF-A for VEGFR-1 is 10-fold stronger than its affinity for VEGFR-2; nonetheless, most 
VEGF-A–mediated downstream signaling events associated with angiogenesis require 
VEGFR-2 activation (Waltenberger et al., 1994, Zachary 2003, Szala 2009). Binding of 
VEGFR-2 to VEGF induces dimerization and consequent phosphorylation of a subset of 
intracellular tyrosine residues (Rydén et al., 2003, Chen et al., 2010). 
VEGFR-3 has been detected in embryonic epithelial cells. In mature tissue it is present 
almost exclusively in the lymphatic vessel epithelium cells, which indicates its participation 
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in lymphangiogenesis. The receptor does not recognise VEGF-A but does bind with VEGF-C 
and VEGF-D (Barańska et al., 2005; Namiecińska et al., 2005).  
In the 1990s, soluble forms of sVEGFR-1, unanchored in the cell membrane, were 
discovered. The particulars of the biochemical structure of sVEGFR-1 remain to be 
determined, but we know that by binding with each isoform of VEGF they serve as negative 
angiogenesis regulators and inhibit the formation of blood vessels in neoplastic tumours 
(Thielemann et al., 2010).  
2.4 Regulation of VEGF expression 
VEGF expression is regulated by a number of mechanisms, the most important of which is 
hypoxia. In conditions of lowered oxygen partial pressure, a sudden increase can be 
observed in terms of the presence of hypoxia inducible factor - HIF-1ǂ – which activates the 
VEGF gene promoter – HRE (hypoxia response element), thus intensifying VEGF expression 
(Breier & Risau, 1996; Fang et al., 2001; Ferrara, 1999; Namiecińska et al., 2005; Papetti & 
Herman, 2002; Rosen, 2002).  
The gene’s stimulation independent of HIF-1 has also been observed as a result of hypoxia. 
Due to low oxygen pressure, accumulation of adenosine may occur activating its receptor 
A2 and causing an increase of cAMP concentration, which in turn leads to elevated levels of 
mRNA for VEGF. Stimulation of VEGF expression can also be due to the influence of 
cytokines: EGF, TGF-ǃ, KGF, PGF2, IGF-1, interleukin - IL-1, IL -5, IL-6, IL-9, IL-13, or due to 
a mutation of certain oncogenes leading to a neoplastic transformation (Barańska et al., 2005; 
Breier & Risau, 1996; Gruchlik et al., 2007, Xue et al., 2009). An example of the latter case 
may be the mutation of gene p-53, which stimulates VEGF expression.  
3. VEGF expression in tumours  
3.1 VEGF expression profiles in human tumours 
The opinion prevalent in literature is that increased vascular density may result from 
overexpression of proangiogenic factors, particularly VEGF (Han et al., 2001).  
The induction of vessel growth is a process closely regulated by positive and negative 
angiogenesis regulators. In a mature organism, the two balance each other out, thus 
preventing vessel carcinogenesis. Any distortion of the balance results in the increased 
production and action of one or more proangiogenic factors, which leads to the stimulation 
of angiogenesis (Jośko et al., 2000; Conti, 2002).  
It has been suggested by a number of researchers that VEGF is a mitogen of epithelium cells 
and a strong factor inducing increased vessel permeability. It plays a vital role in the process 
of neovascularisation, tumour growth and metastasis (Baillie et al., 2001; Barańska et al., 
2005; Chhieng et al., 2003; Dvorak, 2002; Grunstein et al., 1999; Hicklin & Ellis, 2005; Kraft et 
al., 1999; Litwiniu et al., 2007; Poon et al., 2003; Zheng et al., 2003). Chechlińska also 
observes that it can activate specific types of integrins on neoplastic cells, which increases 
invasiveness by allowing tumour cells to anchor to degraded elements of the extracellular 
matrix (Chechlińska, 2003).  
There are a number of publications pertaining to the assessment of immunohistochemical 
expression of VEGF receptors in cancerous tissues. In the research, anti-VEGF antibodies 
were used to show receptors in endothelial cells. Takahashi observed elevated expression of 
the KDR/Flk-1 receptor for VEGF in metastased malignant colorectal cancers, as compared 
to non-metastased cancers (Takahashi et al., 1995).  
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Research has also been conducted on patients suffering from lung cancer (Oshika et al., 
1998; Yuan et al., 2001) and women diagnosed with malignant breast cancer (Adams et al., 
2000; Lewis et al., 2000; Terman & Stoletov, 2001). Overexpression of the vascular 
endothelial growth factor correlated with tumour growth, development of new vessels, and 
early relapse of the neoplastic disease.  
With the use of the real-time PCR exam, the presence of VEGF mRNA can be determined in 
tumour cells. The highest VEGF mRNA levels have been observed in malignant tumour 
tissue contiguous with necrotic areas (Ferrara & Davis-Smyth 1997; Restucci et al., 2002).  
Increased VEGF expression, both in terms of mRNA in neoplastic tissues and the protein 
itself in blood plasma, serum and urine, has been observed in numerous types of neoplastic 
disease in humans (Ferrara & Davis-Smyth, 1997; Łojko & Komarnicki, 2004). Elevated 
VEGF concentrations in blood plasma have been noted in patients diagnosed with colorectal 
cancer, lung cancer, and breast cancer in women. It typically constituted a bad prognosis 
and indicated the presence of distant metastases (Chhieng et al., 2003; Ferrara & Davis-
smyth, 1997; Han et al., 2001; Litwiniuk et al., 2007; Zheng et al., 2003; Kopczyńska et al., 
2008; Wójcik et al., 2010).  
Overproduction of VEGF has also been observed in neoplastic cells of aberrant ovaries. The 
growth factor was identified in the peritoneal effusions from female patients diagnosed with 
malignant neoplastic growths, which suggests its secretion by cancerous cells 
(Gawrychowski et al., 1997).  
Elevated VEGF levels have also been noted in hematologic hyperplasia. In myeloid 
leukaemia, elevated VEGF levels correlated with shorter survivability and lower probability 
of full remission (Łojko & Komarnicki, 2004).  
Kozaczka et al. observed significantly higher levels of serum VEGF in patients diagnosed 
with surgical colorectal andenocarcinoma, when compared to the control population. They 
concluded that the level of vascular endothelial growth factor was the only statistically 
significant parameter of prognostic value (Kozaczka et al., 2004).  
Elevated levels of VEGF expression, related to bad prognoses and high likelihood of 
metastasis, have been observed in various types of malignant tumours in humans (Epstein 
et al., 2001; Poon et al., 2003; Yu et al., 2002; Yuan et al., 2001). A correlation has also been 
observed between the VEGF value and the level of malignancy in tumours of: lungs, breasts, 
thyroids, stomachs, intestines, kidneys, bladders, ovaries, oral cavities, as well as 
angiosarcomas, and nervous system neoplasms (Chao et al., 2001; Han et al., 2001; Nicosia, 
1998; Yuan et al., 2001). 
Research has also been conducted into the expression of serum VEGF in patients suffering 
from melanoma. Elevated VEGF levels in the serum were observed in patients with 
advanced neoplastic process. It indicated significantly shorter periods of remission and, as 
suggested by the author, was of prognostic value (Ascierto et al., 2004;Yu et al., 2002).  
Available literature devotes significant attention to the correlation between the vessel 
density in cancerous tissue and the expression of VEGF in blood serum or tumour cells 
(Adams et al., 2000; Ferrara, 1999; Kondo et al., 2000; Loggini et al., 2003; Takahashi et al., 
1995; Zheng et al., 2003). 
Said correlation has been observed in squamous skin carcinomas in humans. Some 
researchers suggest that the correlation between the number of vessels and the increased 
expression of vascular endothelial growth factor mRNA can prove valuable in determining 
the malignancy level of such cancers (Loggini et al., 2003). The development of vessels 
accompanied by increased concentrations of VEGF mRNA as well as of the protein itself in 
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tumour tissues has also been observed in cases of colorectal adenoma (Kondo et al., 2000; 
Takahashi et al., 1995) and breast cancer (Adams et al., 2000) in humans, where it indicated 
unfavourable prognoses.  
It is assumed that the negative correlation between the number of vessels in a tumour and 
the level of VEGF as the main proangiogenic factor may be due to the process known as 
vascular mimicry. It is a process in which angioid channels are formed outside the 
epithelium. Literature indicates that said phenomenon can be observed in the case of 
malignant melanomas (Folberg et al., 2000; McDonald et al., 2000).  
3.2 VEGF expression profiles in dog tumours  
Comparative studies have been performed in respect to human and animal VEGF structure. 
It was demonstrated that all main isoforms of the vascular endothelial growth factor are 
present in dogs, and that amino acid sequences in the areas responsible for binding with 
receptors are identical in humans and animals. Furthermore, it has been observed that 
canine VEGF activates human endothelial cells to the same extent as the human growth 
factor. In dogs, it occurs in tumours at similar volumetric ratios to those observed in human 
malignant tumours (Mohammed et al., 2002; Scheidegger et al., 1999).  
The immunohistochemiacal reaction of VEGF expression has also been studied in squamous 
carcinomas and skin basaliomas in dogs (Maiolino et al., 2004). The presence of the growth 
factor was observed in all squamous cancers, particularly those located in the vicinity of 
toes, while it was not detected in the studied basaliomas. Similar results were obtained in 
the course of research on human squamous carcinoma (Loggini et al., 2003; Oshika et al., 
1998). It is believed that the presence of VEGF in squamous cancers may serve as a viable, 
additional criterion in determining the malignancy and growth capacity of tumours in both 
dogs and humans. 
The growth factor has been determined in the blood serum of dogs diagnosed with 
angiosarcoma. It was observed that elevated VEGF levels in dog blood serum occurred in dogs 
suffering from cancer. It did not, however, correlate with the advancement stage of the disease 
or the size of the tumour (Clifford et al., 2001). Similar results were obtained by Wergin and 
Kaser-Hotz. They observed that in healthy dogs the level of VEGF was indiscernible, while in 
dogs suffering from the neoplastic disease it was high and the obtained results were 
statistically significant (Wergin & Kaser-Hotz, 2004; Wergin et al., 2004).  
Elevated VEGF levels have also been observed in the urine of dogs diagnosed with 
malignant bladder cancer (Mohammed et al., 2002).  
Our own research indicated statistically significant VEGF values in the blood serum of dogs 
suffering from malignant skin neoplasms. An analysis of own research results as well as 
data available in literature suggests that the blood serum levels of VEGF may indeed 
constitute a valuable prognostic criterion and be a viable indicator in early diagnoses of 
carcinomas. Overexpression of the vascular endothelial growth factor observed in malignant 
tumours, confronted with the clinical picture of the neoplasia, may influence the choice of 
treatment and facilitate the prognosis of its therapeutic effect (Sobczyńska-Rak, 2009). 
A study on vascular density in mammary carcinomas in dogs yielded similar results to 
those obtained in humans. The correlation between the number of capillaries and elevated 
VEGF levels was again observed (Restucci et al., 2002).  
In the course of own research, a correlation was observed between vessel density and serum 
VEGF levels in benign and malignant skin cancers in dogs. A negative correlation was 
indicated in the case of oral cancer, while no correlation was observed in the case of 
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mammary cancer. The results indicate that both angiogenesis and the growth factor have 
significant prognostic value in terms of determining the malignancy level of skin cancer. The 
potential value of the same in respect to oral cancer and mammary cancer remains to be 
determined (Sobczyńska-Rak, 2009). 
Research by other authors conducted on dogs suffering from mammary cancer indicates 
that VEGF stimulates the proliferation and migration of endothelial cells and therefore 
influences angiogenesis. However, for a functional vessel to be formed other growth factors 
are required (Restucci et al. 2002; Troy et al., 2006). 
To sum up, overexpression of VEGF in blood serum, bodily fluids, or neoplastic tissue often 
correlates with angiogenesis, growth and metastasis in both human and animal cancers. The 
observed close relations suggest the notion of treating neoplastic disease through inhibiting 
the formation of blood vessels in cancerous tissues. A particularly promising treatment 
approach may prove to be the use of VEGF antibodies (Gruchlik et al., 2007; Stępień-
Wyrobiec et al., 2007, Hashizume et al., 2010) and clinical research into the matter is 
currently being conducted worldwide. In recent years, intensive research has been 
underway into anti-neoplasmic treatments with the use of cytostatic agents in combination 
with agents inhibiting VEGF expression or blocking its receptors. The results so far show 
considerable promise and may constitute a significant breakthhrough in the fight against 
neoplastic disease ( Volk et al., 2011) 
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